Genomic Health-backed Invitae will offer 6.35 million shares priced at $16, raising $101.6m.
Invitae Corporation, a US-based genetic testing technology provider backed by diagnostic testing company Genomic Health, has announced its initial public offering will be $16 a share.
The company is set to issued 6.35m shares on the New York Stock Exchange, raising proceeds of $101.6m.
The amount is higher than the range of $13 to $15 announced last week, when the company expected to issue 5.35 million shares and raise up to $80.3m.
Invitae was spun out of Genomic in 2012…
